University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Chloe Atreya, MD, PhD

Chloe Atreya, MD, PhD

Assistant Clinical Professor, Department of Medicine, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Education

Princeton University,  Princeton NJ, BA, 05/98, Molecular Biology,  Certificate in Visual Art
Yale University,  New Haven,  CT, PhD, 05/04, Pharmacology
Yale University,  New Haven,  CT, MD, 05/05, Medicine
University of Washington,  Seattle,  WA, 06/08, Internal Medicine,  internship and residency
University of California,  San Francisco, 06/10, Medical Oncology,  fellowship
University of California, San Francisco, 06/14, Certificate, Advanced Training in Clinical Research


Professional Experience

  • University of Michigan Medical Center, Ann Arbor, MI
    06/95-09/95 Research Intern in cardiovascular gene therapy with Dr. Elizabeth Nabel
  • University of Washington Affiliated Hospitals, Seattle, WA
    06/05-06/08 Department of Internal Medicine, Internship and Residency, Categorical Track
  • University of California San Francisco, San Francisco, CA
    07/08-07/10 Department of Medicine, Hematology/ Oncology Fellow
    07/10-07/11 Non-ACGME Postdoctoral Fellow
    2011-2013 Adjunct Instructor of Medicine
    2013-present Assistant Clinical Professor

 

Honors & Awards

  • University of Michigan Human Genome Center, Ann Arbor, MI
    1993, 92 Howard Hughes Summer Internships with Dr. Francis Collins
  • Princeton University, Princeton, NJ
    1998 Bachelor of Arts, Molecular Biology, High Honors
    1998 Phi Beta Kappa
    1998 Sigma Xi
    1997 Lucas Graphics Prize for the best graphic image by a Princeton student
  • Yale University School of Medicine, New Haven, CT
    2005 MD-PhD Alumni Award
    2005 Janet M. Glasgow Memorial Achievement Citation, presented by the American Medical Women’s Association to women who graduate at the top of their medical school class
  • 2011
    American Cancer Society Postdoctoral Fellowship 11-183-01-TBG
  • 2011
    Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award
  • 2012
    UCSF Resource Allocation Program Spring 2012 Core Exploratory Award
  • 2012
    Alliance for Clinical Trials in Oncology Foundation Investigator Award
  • 2012
    Pilot Research Award for Junior Investigators, Mt. Zion Health Fund, Gump Cancer Fund from the Resource Evaluation and Allocation Committee, and HDFCCC
  • 2014
    The Ernest H. Rosenbaum MD Commitment to Patient Care Award, UCSF Symptom Management Service
  • 2017
    The Marcus Program in Precision Medicine Innovation Seeding Bold Ideas Award

Selected Publications

  • Atreya, CE, Johnson, EF, Irwin, JI, Dow, A, Massimine, KM, Coppens, I, Stempliuk, V, Beverley, S, Joiner, KA, Shoichet, BK, and Anderson, KS (2003) A Molecular Docking Strategy Identifies Eosin B as a Non-Active Site Inhibitor of Protozoal Bifunctional Thymidylate Synthase-Dihydrofolate Reductase. Journal of Biological Chemistry, 278, 14092-100. PMID: 12556445.
  • Atreya, CE, Johnson, EF, Williamson, J, Chang, S-Y, Liang, P-H, and Anderson, KS (2003) Probing Electrostatic Channeling in Protozoal Bifunctional Thymidylate Synthase-Dihydrofolate Reductase Using Site-Directed Mutagenesis. Journal of Biological Chemistry, 278, 28901-11. PMID: 12754260.
  • Atreya, CE and Anderson, KS (2004) Kinetic Characterization of Bifunctional Thymidylate Synthase-Dihydrofolate Reductase (TS-DHFR) from Cryptosporidium hominis: A Paradigm Shift for TS Activity and Channeling Behavior. Journal of Biological Chemistry, 279 (18), 18314-22. PMID: 14966126.
  • Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM (2012) Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs, (6) 2219-25. PMID: 22270257.
  • Ducker GS, Atreya CE, Simko JS, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DD, Settleman J, Shokat KM, Warren RS (2013) Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene, 2013. PMID: 23542178
  • Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, and Warren RS. PTEN Expression is Consistent in Colorectal Cancer Primaries and Metastases and Associates with Patient Survival. Cancer Medicine, accepted 05/14/2013.